Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 8/2018

01-08-2018 | Melanomas

Melanoma Staging: American Joint Committee on Cancer (AJCC) 8th Edition and Beyond

Authors: Jeffrey E. Gershenwald, MD, Richard A. Scolyer, MD

Published in: Annals of Surgical Oncology | Issue 8/2018

Login to get access

Excerpt

Melanoma staging is a critical tool for communication between physicians and their patients and also assists clinical decision-making and prognostic assessment. It is used for clinical trial design, eligibility, stratification, and analysis. Importantly, it also represents the foundation for reporting in institutional, state, national, and international data registries, which, in turn, facilitate understanding of the broader melanoma landscape. …
Literature
1.
Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med. 2015;373:23–34.CrossRefPubMedPubMedCentral
2.
Long GV, Stroyakovskiy D, Gogas H, et al. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N Engl J Med. 2014;371:1877–88.CrossRefPubMed
3.
Robert C, Schachter J, Long GV, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med. 2015;372:2521–32.CrossRefPubMed
4.
Wolchok JD, Chiarion-Sileni V, Gonzalez R, et al. Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med. 2017;377:1345–56.CrossRefPubMedPubMedCentral
5.
Long GV, Hauschild A, Santinami M, et al. Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma. N Engl J Med. 2017;377:1813–23.CrossRefPubMed
6.
Weber J, Mandala M, Del Vecchio M, et al. Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma. N Engl J Med. 2017;377:1824–35.CrossRefPubMed
7.
Gershenwald JE, Scolyer RA, Hess KR, et al. Melanoma of the skin. In: Amin MB, et al. (eds) AJCC cancer staging manual. Switzerland: Springer, 2017:563–85.CrossRef
8.
9.
Gress DM, Edge SB, Greene FL, et al. Principles of cancer staging. In: Amin MB, et al. (eds) AJCC cancer staging manual. Switzerland: Springer, 2017:3–30.CrossRef
10.
Gimotty PA, Elder DE, Fraker DL, et al. Identification of high-risk patients among those diagnosed with thin cutaneous melanomas. J Clin Oncol. 2007;25:1129–34.CrossRefPubMed
11.
Green AC, Baade P, Coory M, et al. Population-based 20-year survival among people diagnosed with thin melanomas in Queensland, Australia. J Clin Oncol. 2012;30:1462–7.CrossRefPubMed
12.
Lo SN, Scolyer RA, Thompson JF. Long-term survival of patients with thin (T1) cutaneous melanomas: a Breslow thickness cut point of 0.8 mm separates higher-risk and lower-risk tumors. Ann Surg Oncol. 2018;25:894–902.CrossRefPubMed
13.
Gershenwald JE, Scolyer RA, Hess KR, et al. Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017;67:472–92.
14.
Andtbacka RH, Gershenwald JE. Role of sentinel lymph node biopsy in patients with thin melanoma. J Natl Compr Canc Netw. 2009;7:308–17.CrossRefPubMed
15.
Cordeiro E, Gervais MK, Shah PS, et al. Sentinel lymph node biopsy in thin cutaneous melanoma: A systematic review and meta-analysis. Ann Surg Oncol. 2016;23:4178–88.CrossRefPubMed
16.
Han D, Zager JS, Shyr Y, et al. Clinicopathologic predictors of sentinel lymph node metastasis in thin melanoma. J Clin Oncol. 2013;31:4387–93.CrossRefPubMed
17.
Murali R, Haydu LE, Quinn MJ, et al. Sentinel lymph node biopsy in patients with thin primary cutaneous melanoma. Ann Surg. 2012;255:128–33.CrossRefPubMed
18.
Wong SL, Faries MB, Kennedy EB, et al. Sentinel lymph node biopsy and management of regional lymph nodes in melanoma: American Society of Clinical Oncology and Society of Surgical Oncology Clinical Practice Guideline Update. Ann Surg Oncol. 2018;25:356–77.CrossRefPubMed
19.
Wong SL, Faries MB, Kennedy EB, et al. Sentinel lymph node biopsy and management of regional lymph nodes in melanoma: American Society of Clinical Oncology and Society of Surgical Oncology Clinical Practice Guideline Update. J Clin Oncol. 2018;36:399–413.CrossRefPubMed
20.
Melanoma of the skin. In: Edge SB, et al. (eds) AJCC cancer staging manual. Philadelphia: Springer, 2010:325–46.
21.
Faries MB, Thompson JF, Cochran AJ, et al. Completion dissection or observation for sentinel-node metastasis in melanoma. N Engl J Med. 2017;376:2211–22.CrossRefPubMedPubMedCentral
22.
Leiter U, Stadler R, Mauch C, et al. Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma (DeCOG-SLT): a multicentre, randomised, phase 3 trial. Lancet Oncol. 2016;17:757–67.CrossRefPubMed
23.
Gershenwald JE, Andtbacka RH, Prieto VG, et al. Microscopic tumor burden in sentinel lymph nodes predicts synchronous nonsentinel lymph node involvement in patients with melanoma. J Clin Oncol. 2008;26:4296–303.CrossRefPubMedPubMedCentral
24.
van der Ploeg AP, van Akkooi AC, Haydu LE, et al. The prognostic significance of sentinel node tumour burden in melanoma patients: an international, multicenter study of 1539 sentinel node-positive melanoma patients. Eur J Cancer. 2014;50:111–20.CrossRefPubMed
25.
Scolyer RA, Li LX, McCarthy SW, et al. Micromorphometric features of positive sentinel lymph nodes predict involvement of nonsentinel nodes in patients with melanoma. Am J Clin Pathol. 2004;122:532–9.CrossRefPubMed
26.
Murali R, Cochran AJ, Cook MG, et al. Interobserver reproducibility of histologic parameters of melanoma deposits in sentinel lymph nodes: implications for management of patients with melanoma. Cancer. 2009;115:5026–37.CrossRefPubMed
27.
28.
Mahar AL, Compton C, Halabi S, et al. Critical assessment of clinical prognostic tools in melanoma. Ann Surg Oncol. 2016;23:2753–61.CrossRefPubMed
29.
Kattan MW, Hess KR, Amin MB, et al. American Joint Committee on Cancer acceptance criteria for inclusion of risk models for individualized prognosis in the practice of precision medicine. CA Cancer J Clin. 2016;66:370–4.CrossRefPubMedPubMedCentral
30.
Amin MB, Edge SB, Greene FL, et al. Organization of the AJCC cancer staging manual. In: Amin MB, et al. AJCC cancer staging manual. Switzerland: Springer, 2017) 31–7.CrossRef
31.
Compton CC, Hess, K.R., Halabi, S., et al. Risk models for individualized prognosis in the practice of precision oncology. In: Amin MB, et al. (eds) AJCC cancer staging manual. Switzerland, Springer, 2017:47–52.CrossRef
Metadata
Title
Melanoma Staging: American Joint Committee on Cancer (AJCC) 8th Edition and Beyond
Authors
Jeffrey E. Gershenwald, MD
Richard A. Scolyer, MD
Publication date
01-08-2018
Publisher
Springer International Publishing
Published in
Annals of Surgical Oncology / Issue 8/2018
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-018-6513-7

Other articles of this Issue 8/2018

Annals of Surgical Oncology 8/2018 Go to the issue

Gastrointestinal Oncology

Totally Laparoscopic Transluminal Resection for Gastrointestinal Stromal Tumors Located at the Cardiac Region

Colorectal Cancer

Cytolytic Activity Score to Assess Anticancer Immunity in Colorectal Cancer

Bone and Soft Tissue Sarcomas

Minimally Invasive Versus Open Primary Resection for Retroperitoneal Soft Tissue Sarcoma: A Propensity-Matched Study From the National Cancer Database

Bone and Soft Tissue Sarcomas

Long-Term Outcome After Surgery for a Localized Retroperitoneal Soft Tissue Sarcoma in Elderly Patients: Results from a Retrospective, Single-Center Study

Gastrointestinal Oncology

Preoperative Circulating Tumor DNA in Patients with Peritoneal Carcinomatosis is an Independent Predictor of Progression-Free Survival

Breast Oncology

Walking the Fine Line of Axillary Management in Mastectomy Patients